Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Christos, Lafaras"'
Autor:
Evdokia Mandala, Kyranna Lafara, Dimitrios Kokkinovasilis, Ioannis Kalafatis, Vasiliki Koukoulitsa, Eirini Katodritou, Christos Lafaras
Publikováno v:
Life, Vol 14, Iss 4, p 524 (2024)
Applied cardio-oncology in hematological malignancies refers to the integration of cardiovascular care and management for patients with blood cancer, particularly leukemia, lymphoma, and multiple myeloma. Hematological cancer therapy-related cardioto
Externí odkaz:
https://doaj.org/article/fb885b53cc5d48f0a430900011768674
Autor:
Christos Lafaras, Dimitrios Platogiannis, Eudokia Mandala, George Ilonidis, Nikolaos Barbetakis, Athanasios N. Saratzis, Theodoros Bischiniotis, Panagiotis P. Paraskevopoulos
Publikováno v:
Onkologie. 33:300-304
The primary aim of this study was to evaluate a combined therapeutic intervention, including the dual endothelin receptor antagonist bosentan, in patients with carcinoid heart disease (CaHD). The efficacy of the treatment protocol was investigated us
Autor:
Christos Lafaras, Christos N. Papandreou, Charalambos Andreadis, Lukas F Kontovinis, Alexandros H. Kortsaris, Maria Christopoulou, Despoina Mouratidou, Evangelos Antonakis, George Kouvatseas, Konstantinos Papazisis
Publikováno v:
BMC Cancer, Vol 10, Iss 1, p 489 (2010)
BMC Cancer
BMC Cancer
Background Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that has been approved for the treatment of metastatic renal cell carcinoma. Although the majority of sunitinib-treated patients receive a clinical benefit, almost a third of th
Autor:
Massimo Imazio, Rita Piazza, Dimitrios Platogiannis, Elda Viel, Witold Z. Tomkowski, Marzia DeBiasio, Francesco Santini, Angela Buonadonna, Eugenio Cervesato, Renata Gralec, Massimiliano Berretta, Salvatore Tumolo, Chiara Lestuzzi, Alessandra Bearz, L. Tartuferi, Theodoros Bishiniotis, Christos Lafaras
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 72(3)
Local (intrapericardial) chemotherapy has been reported to be useful for the treatment of neoplastic pericardial disease, but it has never been compared to systemic chemotherapy, a combination of the two and simple pericardial drainage or sclerosis.W
Autor:
Nikolaos, Barbetakis, Theocharis, Xenikakis, Dimitrios, Paliouras, Christos, Asteriou, George, Samanidis, Athanasios, Kleontas, Christos, Lafaras, Dimitrios, Platogiannis, Theodoros, Bischiniotis, Christodoulos, Tsilikas
Publikováno v:
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese. 51(3)
Of oncological patients who have undergone chest radiation therapy, 20% develop radiation-induced constrictive pericarditis. The purpose of this study was to review our clinic's experience of such cases, focusing on survival and the functional outcom
Publikováno v:
Interactive cardiovascular and thoracic surgery. 9(4)
Autor:
George Ilonidis, Theodoros Bischiniotis, Nikolaos Barbetakis, Sofia Papoti, Maria Christopoulou, Athanasios N. Saratzis, Eudokia Mandala, Dimitrios Platogiannis, Christos Lafaras
Publikováno v:
Onkologie. 32(7)
B-type natriuretic peptide (BNP) and N-terminal-pro-BNP (NT-pro-BNP) are important diagnostic tools for patients with suspected cardiac disorders. The aim of this study was to evaluate the predictive value of plasma NT-pro-BNP in identifying cardiac
Autor:
Christos Lafaras, Nikos Barbetakis, Rosalia Valeri, Theodoros Bischiniotis, Eudokia Mandala, Ioannis Venizelos
Publikováno v:
Onkologie. 31(10)
Cardiac tamponade (CT) as the primary clinical manifestation of lymphomas is extremely rare. Angioimmunoblastic T-cell lymphoma (AILT) is characterised by systemic disease usually presenting with generalised peripheral lymphadenopathy, hepatosplenome
Autor:
K. Zervas, Dimitrios Platogiannis, Theodoros Bischiniotis, Eudokia Mandala, Nikolaos Barbetakis, Christos Lafaras, E. Verrou
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 19(10)
Background Multiple myeloma (MM) is thrombogenic as a consequence of multiple hemostatic effects and endothelial damage. Thalidomide has been associated with an increased risk of thromboembolic pulmonary hypertension (PH). PH in the absence of venous